Echocardiographic quantification of left ventricular mass: Prognostic implications

Current Cardiology Reports

Volumn 12, Issue 3, 2010, Pages 277-282

  Swamy, Rajiv S ^a   Lang, Roberto M ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Echocardiography; Left ventricular hypertrophy; Left ventricular hypertrophy regression; Left ventricular mass

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOSARTAN; RAMIPRIL; RENIN INHIBITOR;

CLINICAL TRIAL; DIAGNOSTIC ACCURACY; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; INTERMETHOD COMPARISON; M MODE ECHOCARDIOGRAPHY; MEDICAL ASSESSMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PROGNOSIS; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THREE DIMENSIONAL ECHOCARDIOGRAPHY; TREATMENT PLANNING; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; HEART VENTRICLES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; PROGNOSIS; RISK FACTORS;

EID: 77956395493     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-010-0104-y     Document Type: Review

References (30)

1. Kannel WB, Gordon T, Castelli WP, et al.: Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease: The Framingham Study. Ann Intern Med 1970, 72:813-822.
2. Carini G, Circo A, Dovellini E: Left ventricular mass and cardiovascular morbidity in essential hypertension: The MAVI study. J Am Coll Cardiol 2001, 38:1829-1835.
3. Ghali J, Liao Y, Simmons B, et al.: The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med 1992, 117:831-836.
4. Schillaci G, Verdecchia P, Porcellati C, et al.: Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000, 35:580-586.
5. McLenachan JM, Henderson E, Morris KI, et al.: Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med 1987, 317:787-792.
6. Casale PN, Devereux RB, Kligfield P, et al.: Electrocardiographic detection of left ventricular hypertrophy: Development and prospective validation of improved criteria. J Am Coll Cardiol 1985, 6:572-580.
7. Levy D, Garrison RJ, Savage DD, et al.: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990, 322:1561-1566.
8. Germain P, Roul G, Kastler B, et al.: Inter-study variability in left ventricular mass measurement: Comparison between M-mode echocardiography and MRI. Eur Heart J 1992, 13:1011-1019.
9. Lang RM, Bierig M, Devereux RB, et al.: Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18:1440-1463.
10. Mor-Avi V, Lang RM: The use of real-time three-dimensional echocardiography for the quantification of left ventricular volumes and function. Curr Opin Cardiol 2009, 24:402-409. This is an informative review on application of RT3DE in clinical practice.
11. Mor-Avi V, Sugeng L, Weinart L, et al.: Fast measurement of left ventricular mass with real-time three-dimensional echocardiography: Comparison with magnetic resonance imaging. Circulation 2004, 110:1814-1818.
12. Takeuchi M, Nishikage T, Mor-Avi V, et al. : Measurement of left ventricular mass by real-time three-dimensional echocardiography: Validation against magnetic resonance and comparison with twodimensional and M-mode measurements. J Am Soc Echocardiogr 2008, 21:1001-1005.
13. Bluemke DA, Kronmal RA, Lima JA, et al.: The relationship between left ventricular mass and geometry to incident cardiovascular events: The MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 2008, 52:2148-2155.
14. Okwuosa TM, Hampole CV, Ali J, et al.: Left ventricular mass from gated SPECT myocardial perfusion imaging: Comparison with cardiac computed tomography. J Nucl Cardiol 2009, 16:775-783.
15. Milani RV, Lavie CJ, Mehra MR, et al.: Left ventricular geometry and survival in patients with normal left ventricular ejection fraction. Am J Cardiol 2006, 97:959-963.
16. Nadour W, Biederman RW: Is left ventricular hypertrophy regression important? Does the tool used to detect it matter? J Clin Hyperten (Greenwich) 2009, 11:441-447.
17. Fagard RH, Celis H, Thijs L, et al.: Regression of left ventricular mass by antihypertensive treatment. Hypertension 2009, 54:1084-1091. This is a recent large clinical metaanalysis evaluating the therapeutic effect of antihypertensive therapy on clinical outcomes.
18. Artham SM, Lavie CJ, Milani RV, et al.: Clinical impact of left ventricular hypertrophy and implications for regression. Prog Cardiovasc Dis 2009, 52:153-167.
19. Devereux RB,WachtellK,Gerdts E, et al.: Prognostic significance of left ventricularmass change during treatment of hypertension. JAMA 2004, 292:2350-2356.
20. Klingbeil AU, Schneider M, Martus P, et al.: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003, 115:41-46.
21. Cuspidi C, Esposito A, Negri F, et al.: Studies on left ventricular hypertrophy regression in arterial hypertension: A clear message for the clinician? Am J Hypertens 2008, 21:458-463.
22. Mathew J, Sleight P, Lonn E, et al.: Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001, 104:1615-1621.
23. Devereux RB, Dahlof B, Gerdts E, et al.: Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) trial. Circulation 2004, 110:1456-1462.
24. Devereux RB, Palmieri V, Liu JF, et al.: Progressive hypertrophy regression with sustained pressure reduction in hypertension: The Losartan Intervention for Endpoint Reduction study. J Hypertens 2002, 20:1445-1450.
25. Kannel WB, Schatzkin A: Sudden death: Lessons from subsets in population studies. J Am Coll Cardiol 1985, 5:141B-149B.
26. Verdecchia P, Reboldi G, Gattobigio R, et al.: Atrial fibrillation in hypertension: Predictors and outcome. Hypertension 2003, 41:218-223.
27. Pitt B, Reichek N, Willenbrock R, et al.: Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-left ventricular hypertrophy study. Circulation 2003, 108:1831-1838.
28. Solomon SC, Applebaum E, Manning WJ, et al.: Effect of the direct rennin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009, 119:530-537.
29. Williams B, Lacy PS, Thom SM, et al.: Differential impact of blood pressure lowering drugs on central aortic pressure and clinical outcomes. Circulation 2006, 113:1213-1225.
30. Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996, 275:1507-1513.